Eko Health is a digital health company that specializes in cardiac monitoring and AI-powered software solutions for improved heart disease screening and management.

Eko Health, Inc. (Eko) is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes and AI detection platform, SENSORA™. The company’s FDA-cleared technologies are used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others.

National Institutes of Health

National Institutes of Health (NIH)

Seraph Group

Morningside Venture Investments

Morningside Venture Partners

PROOF Fund

Sand Hill Angels

NTT Venture Capital

Questa Capital Management

Highland Capital Partners

3M New Ventures

Artis Ventures (AV)

DigiTx Partners

Longevity Vision Fund

Eko Health

🎉 We are honored to announce that the FDA has cleared Eko's Low Ejection Fraction (Low EF) AI. For the first time, U.S. healthcare providers can now detect reduced ejection fraction, a key indicator of heart failure, using an Eko stethoscope during routine physical examinations. 

🫀 Developed in collaboration with Mayo Clinic, Eko's Low EF AI marks a major milestone in the early detection of cardiovascular diseases. 

🎙️ Dr. Paul Friedman, Chair of the Department of Cardiovascular Medicine at Mayo Clinic in Rochester, remarked:

"The ability to identify a hidden, potentially life-threatening heart condition using a tool that primary care and subspecialist clinicians are familiar with — the stethoscope — can help us prevent hospitalizations and adverse events. Importantly, since a stethoscope is small and portable, this technology can be used in urban and remote locations and hopefully help address care in underserved areas."

🎙️ Connor Landgraf, co-founder and CEO of Eko Health, highlighted:

"The stethoscope, the most recognizable symbol of healthcare, touches the lives of an estimated 1 billion people around the globe every year. With Eko's Low EF AI, we've transformed the icon of medicine into an AI-powered heart failure early detection tool that can help improve access to care for millions of patients at a fraction of the time and cost of echocardiography. It's been a privilege to work alongside Mayo Clinic in this groundbreaking endeavor."

📰 Read the full press release here: https://lnkd.in/g6wur3Xb

#healthcare #digitalhealth #AI #cardiology #health

Meet the Eko team at ACP Internal Medicine Meeting at booth 738! #IM2024

Learn how Eko’s software, combined with advanced digital stethoscope technology, can help you detect disease earlier.

Great article by Alex Knapp highlighting the significance of early heart disease detection and the role Eko’s newly FDA-cleareI liId AI can play in expediting it.🫀

"Heart disease remains the number one killer of Americans, with nearly 700,000 people dying each year. Over 6 million Americans are estimated to live with heart conditions–though they may not know it. But about half of them have a risk factor where their heart isn’t pumping blood as effectively as it could be — what doctors call “low ejection fraction.” Catching this early can mean the prevention of more serious heart conditions, but it often goes undetected because there are few symptoms."

🔗 Read the full article here: https://lnkd.in/gfRpRV85

This insightful STAT article by Lizzy Lawrence highlights the recent FDA clearance of Eko’s Low Ejection Fraction Detection AI, a significant milestone in cardiology achieved in collaboration with Mayo Clinic.

Eko's CEO Connor Landgraf, along with Mayo Clinic cardiologists Dr. Paul Friedman and Dr. Demilade Adedinsewo, discussed how the Low EF AI signifies a crucial development in the early detection of heart disease, impacting healthcare both in the U.S. and worldwide.

🔗 Read the full article here: https://lnkd.in/e9hUWbef

Join the Eko Team at #ACC2024 for an illuminating real-world deployment poster session on the success of Eko's AI-enabled Heart Disease Detection Platform, SENSORA™. 

📅 Session 1542 - Innovation, Digital Health, and Technology 18 
🔍 Presentation Title: Real-world Deployment Success of an AI-enabled Heart Disease Detection Platform: a Case Study
🗣️ Featuring: Emileigh Mercer Lastowski, OTR/L
📌 When & Where: April 8, 2024, 12:45 PM - 1:30 PM, Hall B4-5

This case study unveils the remarkable journey of SENSORA™, an AI-powered cardiac disease detection platform, demonstrating its groundbreaking success in real-world clinical settings. With a focus on Valvular Heart Disease (VHD), learn how SENSORA™ was seamlessly integrated into the workflows of high-volume healthcare centers in Miami, FL, showcasing its exceptional ease of use, accuracy, and the transformative potential for early disease detection.

Witness firsthand the compelling evidence of how AI can revolutionize patient care, significantly enhancing the ability to detect mod+ VHD early and potentially saving lives through advanced technology.

For further details, visit the disclosure: https://bit.ly/3xaTm3e

COM:EKOHEALTH

Eko Health

Analysis Not Available